Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04881487 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy

Study acronym: ARCADE
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 5, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Enrolling by Invitation to Recruiting
    • Primary completion date: Apr 2026 to Aug 2026
    • Study completion date: Apr 2026 to Feb 2028
    • Site details revised at 3 of 3 sites
    v5
  2. Eligibility criteria shortened, about 1 wordv4
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of May 2021 to Jul 5, 2021
    • Site contacts updated at 3 of 3 sites
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'trials within cohorts' (TwiCs) design in which the effect of additional local ablative therapy compared to current standard of care alone, on survival after recurrence in patients with isolated local pancreatic ductal adenocarcinoma (PDAC) recurrence. The most important secondary endpoint is quality of life. Other secondary endpoints are treatment response, acute and late toxicity, overall survival, progression-free survival, local progression-free survival, distant metastases free survival and reasons for non-eligibility or exclusion.
Trial Details
NCT Number NCT04881487
Lead Sponsor UMC Utrecht
Collaborators: Dutch Pancreatic Cancer Group (DPCG)
Conditions
(from sponsor)		 Recurrent Pancreatic Ductal Adenocarcinoma
Enrollment 174 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov